Last checked at 14 Feb 2017 17:30
For immediate release | 14 February 2017 |
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Application for admission
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that following the exercise of employee share options, application has been made by Alliance for a further 90,222 ordinary shares of 1p each in the Company ("Ordinary Shares") to be admitted to trading on AIM.
It is expected that these new Ordinary Shares, which will rank pari passu in all respects with the existing Ordinary Shares, will be admitted to trading on 20 February 2017.
After admission, Alliance will have 472,716,142 Ordinary Shares in issue.
For further information:
Alliance Pharma plc | + 44 (0) 1249 466966 |
John Dawson, Chief Executive Andrew Franklin, Chief Financial Officer | |
Rob Bellhouse, Company Secretary | |
www.alliancepharma.co.uk | |
Buchanan | + 44 (0) 20 7466 5000 |
Mark Court / Sophie Cowles / Jane Glover | |
Numis Securities Limited | + 44 (0) 20 7260 1000 |
Nominated Adviser: Michael Meade / Freddie Barnfield | |
Corporate Broking: James Black / Toby Adcock |
Notes to editors:
About Alliance Pharma
Alliance, founded in 1998, is an international speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors. Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Company continues to explore opportunities to expand its product portfolio.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.